Management of Atrial Fibrillation in Pregnancy

Introduction to Atrial Fibrillation Management

Atrial fibrillation during pregnancy is associated with increased risk of death and requires prompt evaluation by a multidisciplinary team including cardiologists, gynecologists, neonatologists, maternal medicine specialists, and anesthesiologists 1
The European Society of Cardiology recommends immediate electrical cardioversion in pregnant patients with AF who are hemodynamically unstable or have pre-excited AF to improve maternal and fetal outcomes 1

First-line treatment for atrial fibrillation in pregnancy involves immediate electrical cardioversion, which is safe at all stages of pregnancy, with monitoring of fetal heart rate throughout and after the procedure, and precedes with anticoagulation when appropriate 1, 2
Beta-1 selective blockers, such as metoprolol, are also considered first-line for rate control, while avoiding atenolol due to its association with intrauterine growth restriction 1, 3, 4
Second-line treatment includes digoxin, considered when beta-blockers are ineffective or contraindicated 1
Alternative treatments include non-dihydropyridine calcium channel antagonists like verapamil and diltiazem, which can be used if beta-blockers are contraindicated 2

For persistent atrial fibrillation, electrical cardioversion is considered, especially in women with hypertrophic cardiomyopathy 1
For pharmacological cardioversion in stable patients with structurally normal hearts, intravenous ibutilide or flecainide may be considered, although experience with these agents during pregnancy is limited 1
For longer-term rhythm control, flecainide or propafenone may be considered when rate control drugs are ineffective, while avoiding amiodarone due to potential fetal risks 1

Pregnancy creates a hypercoagulable state with increased thromboembolism risk, necessitating the use of standard risk assessment tools like CHA₂DS₂-VASc as in non-pregnant women 1
Low molecular weight heparin (LMWH) is recommended in the first trimester and after week 36, with frequent monitoring and dose adjustments in the third trimester 1, 2
Vitamin K antagonists (VKAs) are recommended in the second trimester through week 36, but avoided in the first trimester due to risk of miscarriage and teratogenicity, and after week 36 due to risk of fetal intracranial bleeding 2
Direct oral anticoagulants (DOACs) are not recommended during pregnancy due to limited safety data 1

Vaginal delivery is recommended for most women, but contraindicated during VKA treatment due to risk of fetal intracranial bleeding 1
Catheter ablation is generally avoided during pregnancy but may be considered in refractory cases using zero-fluoroscopy techniques 1
Women with mechanical heart valves require special consideration, potentially needing continuous IV unfractionated heparin or dose-adjusted LMWH between weeks 6-12 2

Close monitoring of anticoagulation levels, especially in the third trimester, and regular assessment of maternal and fetal well-being are crucial 1
Continuous evaluation of treatment efficacy and side effects, along with recognition of the potential need for higher doses of anticoagulants during pregnancy due to physiological changes, is important 2
Certain medications like atenolol, VKAs, amiodarone, and DOACs should be avoided or used with caution due to their potential risks during pregnancy 1, 2